PL3070091T3 - Pochodne benzodioksolu jako inhibitory fosfodiesterazy - Google Patents

Pochodne benzodioksolu jako inhibitory fosfodiesterazy

Info

Publication number
PL3070091T3
PL3070091T3 PL16020112T PL16020112T PL3070091T3 PL 3070091 T3 PL3070091 T3 PL 3070091T3 PL 16020112 T PL16020112 T PL 16020112T PL 16020112 T PL16020112 T PL 16020112T PL 3070091 T3 PL3070091 T3 PL 3070091T3
Authority
PL
Poland
Prior art keywords
phosphodiesterase inhibitors
benzodioxole derivatives
benzodioxole
derivatives
phosphodiesterase
Prior art date
Application number
PL16020112T
Other languages
English (en)
Inventor
Simon Feldbaek Nielsen
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of PL3070091T3 publication Critical patent/PL3070091T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
PL16020112T 2010-06-24 2011-06-24 Pochodne benzodioksolu jako inhibitory fosfodiesterazy PL3070091T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35820910P 2010-06-24 2010-06-24
PCT/DK2011/000069 WO2011160632A1 (en) 2010-06-24 2011-06-24 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors
EP11729889.3A EP2585469B1 (en) 2010-06-24 2011-06-24 Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors
EP16020112.5A EP3070091B1 (en) 2010-06-24 2011-06-24 Benzodioxole derivatives as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
PL3070091T3 true PL3070091T3 (pl) 2019-09-30

Family

ID=44351701

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11729889T PL2585469T3 (pl) 2010-06-24 2011-06-24 Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy
PL16020112T PL3070091T3 (pl) 2010-06-24 2011-06-24 Pochodne benzodioksolu jako inhibitory fosfodiesterazy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11729889T PL2585469T3 (pl) 2010-06-24 2011-06-24 Benzodioksol lub związki heterocykliczne benzodiazepiny jako inhibitory fosfodiesterazy

Country Status (29)

Country Link
US (3) US8980905B2 (pl)
EP (2) EP3070091B1 (pl)
JP (2) JP6174997B2 (pl)
KR (1) KR101864578B1 (pl)
CN (1) CN102958937B (pl)
AU (1) AU2011269429B2 (pl)
BR (1) BR112012032813B1 (pl)
CA (1) CA2802895C (pl)
CY (2) CY1117862T1 (pl)
DK (2) DK3070091T3 (pl)
ES (2) ES2584055T3 (pl)
HR (2) HRP20160919T1 (pl)
HU (2) HUE030081T2 (pl)
IL (1) IL223329A (pl)
LT (2) LT2585469T (pl)
MX (1) MX2012014131A (pl)
MY (1) MY157481A (pl)
NZ (1) NZ603895A (pl)
PL (2) PL2585469T3 (pl)
PT (2) PT3070091T (pl)
RS (2) RS58945B1 (pl)
RU (1) RU2583787C2 (pl)
SG (1) SG186140A1 (pl)
SI (2) SI3070091T1 (pl)
TR (1) TR201909709T4 (pl)
TW (1) TWI507410B (pl)
UA (1) UA109140C2 (pl)
WO (1) WO2011160632A1 (pl)
ZA (1) ZA201209031B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083099A1 (en) * 2012-11-30 2014-06-05 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
JP6785666B2 (ja) 2014-06-23 2020-11-18 レオ ファーマ アクティーゼルスカブ １，３−ベンゾジオキソール複素環化合物の調製方法
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
DK3390407T3 (da) * 2015-12-18 2023-11-06 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
AU2018286964B2 (en) 2017-06-20 2022-04-14 UNION therapeutics A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2019115776A1 (en) 2017-12-15 2019-06-20 Leo Pharma A/S Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
MX2020010999A (es) 2018-04-18 2021-01-20 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR20210117300A (ko) * 2019-01-15 2021-09-28 유니온 테라퓨틱스 에이/에스 포스포디에스테라제 억제제를 함유하는 변형 방출 정제 제형
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
KR20220041130A (ko) * 2019-07-24 2022-03-31 콘스텔레이션 파마슈티칼스, 인크. 암 치료를 위한 병용 요법에서의 ezh2 억제
CN112552276B (zh) * 2019-09-25 2023-03-21 中国科学院上海药物研究所 苯并氧杂卓-5-酮类化合物及其制备方法和用途
KR20230159485A (ko) * 2021-03-22 2023-11-21 유니온 테라퓨틱스 에이/에스 오리스밀라스트를 사용한 화농땀샘염의 치료
GB202205715D0 (en) 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
HK1000785A1 (en) 1995-05-19 2006-06-30 Kyowa Hakko Kogyo Co., Ltd Oxygen-containing heterocyclic compounds
HUP0100042A3 (en) * 1996-05-20 2003-01-28 Darwin Discovery Ltd Cambridge Benzofuran carboxamides medicaments containing the same and their therapeutic use
AU4967697A (en) 1996-11-19 1998-06-10 Kyowa Hakko Kogyo Co. Ltd. Oxygenic heterocyclic compounds
JP2005060375A (ja) * 2003-07-28 2005-03-10 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
PL1831227T3 (pl) * 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
PL2114951T3 (pl) * 2007-02-28 2014-10-31 Leo Pharma As Nowe inhibitory fosfodiesterazy
ZA200905371B (en) * 2007-02-28 2010-10-27 Leo Pharma As Novel phosphodiesterase Inhibitors
MX2014006812A (es) * 2011-12-21 2014-10-13 Leo Pharma As [1,2,4] triazolopiridinas y su uso como inhibidores de fosfodiesterasa.

Also Published As

Publication number Publication date
LT3070091T (lt) 2019-07-25
EP2585469A1 (en) 2013-05-01
SI2585469T1 (sl) 2016-11-30
TWI507410B (zh) 2015-11-11
DK2585469T3 (en) 2016-08-29
TR201909709T4 (tr) 2019-07-22
SG186140A1 (en) 2013-01-30
AU2011269429A1 (en) 2012-12-20
CN102958937A (zh) 2013-03-06
TW201206940A (en) 2012-02-16
CY1122201T1 (el) 2020-11-25
PT2585469T (pt) 2016-08-29
PT3070091T (pt) 2019-07-22
KR20130038341A (ko) 2013-04-17
US20150111915A1 (en) 2015-04-23
CN102958937B (zh) 2016-03-30
NZ603895A (en) 2014-10-31
BR112012032813A2 (pt) 2016-11-08
RS55104B1 (sr) 2016-12-30
JP2016164168A (ja) 2016-09-08
WO2011160632A1 (en) 2011-12-29
HRP20191136T1 (hr) 2019-09-20
HK1182699A1 (zh) 2013-12-06
IL223329A (en) 2017-01-31
HUE044301T2 (hu) 2019-10-28
UA109140C2 (uk) 2015-07-27
LT2585469T (lt) 2016-10-10
CY1117862T1 (el) 2017-05-17
SI3070091T1 (sl) 2019-08-30
RU2583787C2 (ru) 2016-05-10
MX2012014131A (es) 2013-01-29
KR101864578B1 (ko) 2018-06-07
MY157481A (en) 2016-06-15
EP3070091B1 (en) 2019-04-17
ES2584055T3 (es) 2016-09-23
US9637499B2 (en) 2017-05-02
HRP20160919T1 (hr) 2016-10-07
EP2585469B1 (en) 2016-05-25
US9273064B2 (en) 2016-03-01
US20130123291A1 (en) 2013-05-16
RU2013103079A (ru) 2014-07-27
EP3070091A1 (en) 2016-09-21
ES2733092T3 (es) 2019-11-27
DK3070091T3 (da) 2019-07-08
JP6174997B2 (ja) 2017-08-02
CA2802895C (en) 2019-05-21
IL223329A0 (en) 2013-02-03
CA2802895A1 (en) 2011-12-29
BR112012032813B1 (pt) 2022-02-01
ZA201209031B (en) 2014-02-26
JP2013529602A (ja) 2013-07-22
RS58945B1 (sr) 2019-08-30
PL2585469T3 (pl) 2017-07-31
US8980905B2 (en) 2015-03-17
HUE030081T2 (en) 2017-04-28
US20160022657A1 (en) 2016-01-28
AU2011269429B2 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
HUE044301T2 (hu) Benzodioxol-származékok, mint foszfodiészteráz inhibitorok
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
GB201016880D0 (en) Phosphodiesterase inhibitors
ZA201301951B (en) Benzimidazole derivatives as p13 kinase inhibitors
IL224751A (en) Pyrimidine derivatives as fak inhibitors
ZA201207285B (en) Arylethynyl derivatives
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
WO2011106574A9 (en) Inhibitors for antiviral use
ZA201207636B (en) Heteroaryl imidazoline derivatives as jak inhibitors
IL232358A0 (en) Inhibitors of phosphodiesterase type 10a
ZA201109340B (en) Pyrimidinones as pi3k inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
ZA201209029B (en) Novel pyrimidine derivatives
GB201018996D0 (en) Novel ROCK inhibitors
EP2521451A4 (en) INHIBITORS OF THE HEDGEHOG PATH
EP2379538A4 (en) HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
GB201018597D0 (en) Inhibitors
GB201006605D0 (en) Novel inhibitors
GB201003502D0 (en) Novel inhibitors
GB201003936D0 (en) Novel inhibitors
GB201003395D0 (en) Novel rock inhibitors